Toripalimab Combined With Radiotherapy in the Treatment of Oligometastatic Nasopharyngeal Carcinoma

Trial Details

NCT ID

NCT05147844

Phase

PHASE2

Sponsor

Xinqiao Hospital of Chongqing

Status

RECRUITING

Cancer Type

Nasopharyngeal Head and Neck Cancer

Interventions

• Toripalimab

Locations (sample)

• Chongqing, Chongqing Municipality, China|29.56026,106.55771
• Chongqing, Chongqing Municipality, China|29.56026,106.55771

Key Eligibility Criteria

• Must have signed written informed consent and able to comply with study procedure
• 18-75 years old
• Histologically or cytologically confirmed nasopharyngeal carcinoma
• Pathology or imaging confirmed metastatic nasopharyngeal carcinoma.( Clinical stage of IVB according to the 8th edition of AJCC)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.